Sociedad Americana de Hirudoterapia

Heparin coagulant super-sensitivity during leech therapy

Case report published in Thrombosis Journal (2026)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportSeguridad y control de infeccionesEnsayos clínicosRong Z et al. · Thrombosis journal, 2026

Abstract

BACKGROUND: Leech therapy is used in diverse ways in the medical field, such as for flap salvation and for treatment of osteoarthritis. While bleeding is a recognized adverse effect, severe coagulopathy is rare and underreported, especially when compounded by concurrent anticoagulant use. CASE PRESENTATION: We present a case of a 76-year-old female undergoing leech therapy in combination with systemic heparin for free flap salvage following partial glossectomy and neck dissection. Shortly after initiating both therapies, the patient developed marked coagulopathy, evidenced by prolonged activated partial thromboplastin time (aPTT), elevated thrombin time, and persistent bleeding from the surgical site. Laboratory results suggested synergistic anticoagulant effects of heparin and hirudin, the potent direct thrombin inhibitor secreted by medicinal leeches. Despite discontinuation of systemic heparin, bleeding persisted until leech therapy was halted. The patient received 8 units of packed red blood cells (pRBCs) during the treatment course. Coagulation markers normalized after cessation of leech therapy, with no further bleeding events. CONCLUSIONS: This case highlights a potentially underrecognized risk of coagulopathy in patients undergoing combined leech and systemic anticoagulation therapy. The mechanistically distinct pathways of heparin and hirudin may act synergistically to impair both free and clot-bound thrombin activity. Given the absence of formal guidelines for coagulopathy monitoring in such cases, we propose daily assessment of coagulation markers including aPTT, PT/INR, and a one-time measurement of thrombin time and anti-Xa levels after treatment initiation. This report underscores the need for standardized protocols and further research to guide safe implementation of leech therapy, particularly in patients receiving systemic anticoagulation.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article

Resumen

Case of unexpected heparin coagulant super-sensitivity in a patient receiving medicinal leech therapy — important safety signal for combined heparin-MLT regimens.

Por qué esto importa para la hirudoterapia

This case report describes a 76-year-old female who developed marked coagulopathy—prolonged aPTT, elevated thrombin time, and persistent surgical-site bleeding—during concurrent leech therapy and systemic heparin for free flap salvage following partial glossectomy, requiring 8 units of packed red blood cells before resolution upon leech therapy cessation. Laboratory findings suggested synergistic anticoagulant effects between heparin and hirudin via mechanistically distinct pathways. This is directly relevant to ASH's domain, highlighting a critical safety consideration in hirudotherapy: the potential for exaggerated coagulopathy when medicinal leech application is combined with systemic anticoagulation. The authors propose monitoring protocols including daily aPTT, PT/INR, and one-time thrombin time and anti-Xa measurement. However, this is a single case report, and the proposed monitoring recommendations are not derived from controlled studies, formal guidelines, or systematic evidence.

Citación

Heparin coagulant super-sensitivity during leech therapy.

Rong Z et al. · Thrombosis journal, 2026

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.